Tripla negatív emlőrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-L1 26
• HER2 24
• PD-1 36
• BRCA1 5
• STAT3 1
• STING 0
• EGFR 4
• PI3K 1
• BRCA2 2
• TP53 1
• AKT 0
• PARP 1
• mTOR 0
• TROP2 6
• AR 1
• PTEN 0
• CDK4/6 3
• VEGF 4
• HIF-1 0
• MYC 0
• GPX4 0
• YAP 0
• CTNNB1 0
• JAK 1
• HDAC 0
• MAPK 0
• BCL-2 0
• CXCR4 1
• ERK 0
• NRF2 0
• PPAR 0
• B7-H3 4
• EZH2 0
• FAK 0
• PRMT5 0
• CD47 0
• HSP90 0
• PSMA 4
• IL-6 0
• PIK3CA 2
• CTLA-4 1
• HER3 2
• TNF 0
• COX-2 0
• IGF1R 0
• MEK 0
• FGFR 0
• MDM2 2
• MET 0
• MUC1 3
• NLRP3 0
• PALB2 0
• AMPK 0
• CD40 0
• CSF1R 1
• JNK 0
• METTL3 0
• MMP-9 0
• PKM2 0
• SIRT1 0

6+ intézményből 6, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R15

  Mechanotransduction from the tumor microenvironment to the nuclear envelope protein emerin enables nuclear softening during cancer metastasis

  Rowan University· Glassboro, Egyesült Államok· 564 078 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NCI · R44

  Enriching and expanding tumor-reactive CD8 T-cells to treat breast cancer

  Agonox, Inc.· Portland, Egyesült Államok· 977 639 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · K99

  Unlocking Natural Killer cell potential to combat breast cancer metastasis

  University of Colorado Denver· Aurora, Egyesült Államok· 141 337 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R43

  Analytical Variables and Clinical Utility of AKT1 Mutation Prediction in Breast Cancer Using Deep Learning on Histopathology Images

  Imagenomix Corp.· Brooklyn, Egyesült Államok· 157 826 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R43

  Stable, highly potent and safe lead peptide drug conjugate for the treatment of triple-negative breast cancer.

  Oncotherapy Solutions, Llc· Seattle, Egyesült Államok· 400 000 USD awarded in fiscal year 2026· until 2027. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer

  Cardiff University· Cardiff, Egyesült Királyság· EU contribution 260 348 EUR· until 2029. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancer (MAP-BC)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 252 180 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Biomimetic MXene Nanoplatforms for Targeted Combination Therapy of Triple-Negative Breast Cancer (BioMIX)

  Latvijas Universitate· Riga, Lettország· EU contribution 1 147 740 EUR· until 2030. okt.· 12 countries

• European Commission (Horizon Europe) · HORIZON-EIC

  Next generation therapeutic vaccine for targeted cancer treatment (VacciNEXT)

  Basinnov Life Sciences Unipessoal Lda· Lisboa, Portugália· EU contribution 2 827 529 EUR· until 2029. szept.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Co-culture System with Microfluidics and Onboard Sensors for Breast Cancer study (CoSMOS-BC)

  Universidad del Pais Vasco/ Euskal Herriko Unibertsitatea· Leioa, Spanyolország· EU contribution 209 915 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

10 of 463 running projects, newest first. Listed amounts together: 224,4 M USD + 18,5 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Breast Cancer BRCA1 Carriers: a Pilot Study

  NCT05062174· Indiana University· Frissítve: 2022. dec. 15.

  “PI decision to cancel research”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

  NCT01889238· Pfizer· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 46
• Organoids 9
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 10
• Gene Expression Profiling 110
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 4
• Exome Sequencing 5
• Proteomics 32
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 49
• Liquid Biopsy 4
• Circulating Tumor DNA 16
• Xenograft Model Antitumor Assays 254
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 34
• Machine Learning 28
• Deep Learning 15
• Cohort Studies 21
• Genome-Wide Association Study 3

• B cell receptor-based hybridoma enrichment enables discovery of antibodies against intracellular tumor antigens.

  Front Immunol, 2026. júl.

• eFluor 450 Enables Superior Detection of Intracellular Staphylococcus aureus in High-Autofluorescence Triple-Negative Breast Cancer Cells.

  Cytometry A, 2026. febr.

• Bifidobacterium-derived membrane vesicles inhibit triple-negative breast cancer growth by inducing tumor cell apoptosis.

  Mol Biol Rep, 2023. júl.

• Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells.

  Int J Radiat Oncol Biol Phys, 2021. febr.

• Differential sensitivities of triple-negative breast cancer stem cell towards various doses of vitamin C: An insight into the internal antioxidant systems.

  J Cell Biochem, 2020. nov.

• Differential effects of alliin and allicin on apoptosis and senescence in luminal A and triple-negative breast cancer: Caspase, ΔΨm, and pro-apoptotic gene involvement.

  Fundam Clin Pharmacol, 2020. máj.

• Reverse Screening Bioinformatics Approach to Identify Potential Anti Breast Cancer Targets Using Thymoquinone from Neutraceuticals Black Cumin Oil.

  Anticancer Agents Med Chem, 2019. jan.

• Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment.

  Anticancer Res, 2017. dec.

• Curcumin suppresses 4-hydroxytamoxifen resistance in breast cancer cells by targeting SLUG/Hexokinase 2 pathway.

  Biochem Biophys Res Commun, 2016. márc.

• A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells.

  Cell Oncol (Dordr), 2016. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.